Lunsumio 1 mg/1 ml
Lunsumio 1 mg/1 ml is a medicine authorised by Swissmedic under authorisation number 68314. The authorisation holder is Roche Pharma (Schweiz) AG. The medicinal product code is Biotechnological medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 09 February 2023 and the authorisation is limited until 09 February 2027. ATC code L01FX25 places the medicine in the group Antineoplastic agents.
| Authorisation number | 68314 |
|---|---|
| Name | Lunsumio 1 mg/1 ml |
| Full name | Lunsumio 1 mg/1 ml, Konzentrat zur Herstellung einer Infusionslösung |
| Authorisation holder | Roche Pharma (Schweiz) AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01FX25 |
| First authorisation | 09 February 2023 |
| Authorisation validity | 09 February 2027 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Lunsumio 1 mg/1 ml, Konzentrat zur Herstellung einer Infusionslösung | A | 09 February 2023 |
| 2 | Lunsumio 30 mg/30 ml, Konzentrat zur Herstellung einer Infusionslösung | A | 09 February 2023 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 1 | Durchstechflasche(n) | L01FX25 | 07.16.1. | A |
| 2 | 1 | Durchstechflasche(n) | L01FX25 | 07.16.1. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Lunsumio 1 mg/1 ml authorised in Switzerland?
Yes. Lunsumio 1 mg/1 ml is authorised by Swissmedic under authorisation number 68314, data as of 01 September 2026. The authorisation is limited until 09 February 2027.
Which dispensing category does Lunsumio 1 mg/1 ml have?
Lunsumio 1 mg/1 ml is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of Lunsumio 1 mg/1 ml?
The authorisation holder is Roche Pharma (Schweiz) AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.